Clinical Trial Update: Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine hydrochloride in combination with tanespimycin for recurrent advanced ovarian epithelial cancer or primary peritoneal cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-07-10